Quantcast

Latest lung cancer Stories

2014-10-30 08:37:13

Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers IRVING, Texas, Oct. 30, 2014 /PRNewswire/ -- Caris Life Sciences today announced the presentation of data from two large studies in which Caris Molecular Intelligence(TM), the company's panomic, comprehensive tumor profiling service, facilitated the molecular analysis of lung tumors. The biomarker...

2014-10-30 04:21:00

LUGANO, Switzerland, October 30, 2014 /PRNewswire/ -- In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue and improve health-related quality of life in patients with advanced NSCLC cachexia. Helsinn Group, the Company focused on building quality cancer care, announces that anamorelin, its investigational novel once-daily ghrelin receptor agonist for the treatment of cancer anorexia-cachexia syndrome...

2014-10-29 23:01:58

ReportsnReports.com adds “Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma” to its store. The report analyzes innovation in NSCLC in the context of the overall pipeline and current market landscape. Dallas, Texas (PRWEB) October 30, 2014 Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current...

2014-10-29 12:27:14

Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo...

2014-10-29 08:33:08

Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct. 29, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel...

2014-10-29 08:28:31

LUNG FORCE is a New National Movement Aimed at Fighting Lung Cancer in Women CHICAGO, Oct. 29, 2014 /PRNewswire/ -- As part of Lung Cancer Awareness Month this November, Emmy-nominated actress and author Valerie Harper, Grammy-nominated singer/songwriter Jewel, country music singer Kellie Pickler and female NASCAR standout Mackena Bell are teaming up with the American Lung Association's LUNG FORCE to raise awareness and much needed funds to help confront lung cancer in women....

2014-10-28 23:03:44

The family medical practice is now an accredited Lung Cancer Screening Center. Evans, GA (PRWEB) October 28, 2014 Center for Primary Care has been designated a Lung Cancer Screening Center by the American College of Radiology (ACR). The ACR Lung Cancer Screening Center designation is a voluntary program which recognizes facilities that have committed to practice safe, effective diagnostic care for individuals at the highest risk for lung cancer. In order to receive this elite...

2014-10-28 12:31:20

DENVER, Oct. 28, 2014 /PRNewswire/ -- Pharmatech seeking biomarker targeting lung cancer studies. Following the successful launch of AccessPPM, Pharmatech has begun its series of clinical trials in a portfolio of studies planned to treat the different molecular drivers of lung cancer. This approach, which will also be applied for other types of cancer, is designed to identify all of a patient's active biomarkers up front, then provide immediate access to research based treatment...

2014-10-23 12:29:27

Medicare has an ethical obligation to cover low-dose CT scans NEW YORK, Oct. 23, 2014 /PRNewswire-iReach/ -- Lung Cancer Action Network (LungCAN®) members are encouraging Congress to compel the Centers for Medicare and Medicaid Services (CMS) to cover low-dose CT scans for high-risk seniors. In a recently launched online social media campaign, LungCAN members and their constituents are fighting back with Tweets, Facebook posts, and social ads with a message that is loud and clear:...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.